Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 183 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Trivalent influenza virus vaccine Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

NCT01181323
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

NCT00344305
View directory record Official record
Conditions
Healthy
Interventions
Trivalent influenza virus vaccine live, intranasal
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 59 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
16
States / cities
Little Rock, Arkansas • Marietta, Georgia • Bardstown, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 + TIV - Adults and Elderly

NCT00943878
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

NCT00333398
View directory record Official record
Conditions
Influenza
Interventions
CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
10
States / cities
Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

NCT01246999
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV
Biological
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 9 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

NCT03143101
View directory record Official record
Conditions
Influenza, Healthy
Interventions
FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
12
States / cities
Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old

NCT01992107
View directory record Official record
Conditions
Influenza
Interventions
QIVc, TIV1c, TIV2c
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 18 Years
Enrollment
2,333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
88
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Different Doses of Fluzone® Influenza

NCT00253734
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (IM), Fluzone®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 1 Interventional

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

NCT01941758
View directory record Official record
Conditions
Central Nervous System Neoplasm
Interventions
trivalent influenza vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 3, 2026, 3:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

NCT01014806
View directory record Official record
Conditions
Influenza
Interventions
Influenza VLP Vaccine, TIV
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Delivery Routes of Flu Vaccine in Adults

NCT00170547
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Stanford, California • Torrance, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

NCT00980005
View directory record Official record
Conditions
Influenza
Interventions
GSK investigational vaccine GSK1557482A, Fluzone®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
3 Years to 17 Years
Enrollment
2,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
28
States / cities
Birmingham, Alabama • Benton, Arkansas • Huntington Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

NCT06744205
View directory record Official record
Conditions
Influenza, Healthy Volunteers
Interventions
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
1,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

High Dose Influenza Vaccine in Nursing Home - Pilot Study

NCT01720277
View directory record Official record
Conditions
Influenza
Interventions
HD Fluzone Vaccine, SD Fluzone Vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
2,957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Providence, Rhode Island • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 3, 2026, 3:50 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

NCT00662272
View directory record Official record
Conditions
Influenza
Interventions
Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
Biological
Lead sponsor
Colby Pharmaceutical Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 3, 2026, 3:50 PM EDT
Not listed Phase 4 Interventional

Optimizing Influenza Vaccination in Surgical Oncology Patients

NCT01698177
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Results available

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

NCT01215734
View directory record Official record
Conditions
Adult Stem Cell Hematopoetic Transplant
Interventions
High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV), Standard Dose Trivalent Inactivated Flu Vaccine
Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00835926
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

NCT01831934
View directory record Official record
Conditions
MELAS Syndrome
Interventions
Fluzone®
Biological
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 3, 2026, 3:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

NCT00570037
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 3, 2026, 3:50 PM EDT